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Abstract
The effect of a standardized powder made from rosehips on joint pain and stiffness in patients with osteoarthritis has been investigated in 
several clinical studies. The powder is produced by Hyben Vital, Denmark and has been on the market as an herbal remedy in Scandinavia 
for more than a decade. Three studies are of particular interest: (i) A study of 94 patients with early stage osteoarthritis as deﬁ ned by the 
ACR,1 (ii) a study of 100 patients with end stage osteoarthritis, (patients on a waiting list for hip or knee replacement)2 and (iii) a study of 112 
patients with osteoarthritis of different joints3 in which a sub-fraction of patients (n=32) had osteoarthritis of the hand.4
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Early stage osteoarthritis
Winther et al. conducted a study on 94 patients, age > 35 
years, with symptomatic knee and/or hip osteoarthritis, 
according to the clinical and radiological criteria of the 
American College of Rheumatology. These patients were 
not on a waiting list for hip or knee replacement and were 
randomly allocated either to treatment with standardized 
encapsulated rosehip powder (5 g per day), or placebo.1
The study was a double-blind crossover design and 
WOMAC questionnaires were applied at the beginning, 
after 3 weeks, and after 3 months of treatment. Following 
this initial 3 month period, the group initially treated with 
rosehip powder was allocated to placebo and vice versa. 
During the ﬁ rst three weeks of treatment, patients were not 
allowed to change their intake of rescue medication. After 3 
weeks of treatment, patients were allowed to change their 
consumption of paracetamol and synthetic opioids such as 
tramadol and Codein if they wished to. Patients were told 
not to change their consumption of NSAID’s.
Results (primary endpoints): Pain declined as a result 
of active treatment after 3 weeks (delta WOMAC decline: 
7.4 ± 14.9 S.D. as compared to a modest increase in the 
placebo group 2.1 ± 16.8 S.D., p<0.014). After 3 months of 
treatment the WOMAC score in the rosehip powder group 
was practically unchanged and not signiﬁ cantly different 
from placebo, p<0.125. 
An estimate of the consumption of rescue medication such 
as paracetamol showed a signiﬁ cant decline in the rosehip 
powder group, p<0.031 (Fig. 1).
Results (secondary endpoints): Stiffness, ADL and 
patients’ global assessment of disease severity (PGAD) 
tended to decline after three weeks of treatment. All three
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parameters attained statistical signiﬁ cance in favor of active 
treatment after 3 months of treatment, p<0.038, p<0.018 
and p<0.035, respectively.
A Man–Whitney test applied after the initial 3 months 
of treatment did not change the statistical outcome of the 
study and side-effects reported during active treatment 
were comparable to placebo.
End stage osteoarthritis
Warholm et al. conducted a double-blind, parallel, placebo-
controlled, randomized trial on 100 patients with a mean 
age 65 years, all with osteoarthritis of the hip or knee.2
50 patients were given encapsulated Hyben Vital rosehip 
Fig. 1. Change in the consumption of acetaminophen (paracetamol) 
tablets (500 mg) during 3 months active treatment and 3 months 
treatment with placebo. The change for each treatment period is 
calculated as the number of tablets taken during the ﬁ rst two weeks 
of the treatment period minus the number of tablets taken during 
the last two weeks of the same treatment period. (* p<0.031).
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powder for 4 months. The remaining patients were given 
a placebo of similar taste and smell for an identical time 
period. 
All patients had their diagnosis of osteoarthritis of the hip 
or knee veriﬁ ed by radiography less than 12 months before 
the study. All patients had experienced pain for more than 
6 months and were on a waiting list for either hip or knee 
surgery or on a list for ﬁ nal evaluation for surgery.
Primary endpoint measures: Hip joint mobility was 
estimated using a goinometer, which measures how 
many degrees of ﬂ exibility in the joint when tested by the 
researcher (passive ﬂ exion). This improved signiﬁ cantly 
in the rosehip powder group compared with placebo. The 
limitation of ﬂ exion as a result of osteoarthritis was reduced 
by 40% (p<0.033). When hip ﬂ exion was performed actively 
(by the patient) the improvement was still signiﬁ cant in the 
rosehip powder group compared to placebo (p<0.026). 
A similar, but non-signiﬁ cant pattern was observed for 
external and internal rotation. Passive hip joint mobility is 
shown in Fig. 2.
Secondary endpoints: A signiﬁ cantly greater relief from 
joint pain was found in the group receiving standardized 
rosehip powder (p<0.035) than in the placebo group. 65.5% 
responded to active treatment whereas 35% responded to 
placebo. Side-effects reported during active treatment were 
few and comparable to what was reported in the placebo-
group.
Winther and Kharazmi published a sub-study on osteo-
arthritis of the hand,4 data for which was gathered from a 
larger study on osteoarthritis in different joints (reported 
elsewhere).3 In this study 32 patients were given 5 g per 
day of Hyben Vital rosehip powder or placebo 3 months - 
after which the group initially treated with rosehip powder 
was given placebo and vice versa.
The primary efﬁ cacy parameter – pain of the hand – was 
evaluated using a ten step categorical scale for 15 daily 
activities involving the hand. The activities were as follows: 
(i) holding heavy things in your hand, (ii) pouring water from 
a jug, (iii) holding a cup and using cutlery, (iv) wringing out 
a dishcloth, (v) peeling potatoes, (vi) unscrewing a bottle 
top, (vii) getting pills out of a blister pack, (viii) opening a 
milk carton, (ix) tying shoelaces, (x) using a toothbrush, 
(xi) writing with a pen or pencil, (xii) holding a book hand for 
reading, (xiii) using garden tools, (xiv) using a corkscrew or 
tin opener and (xv) picking up and holding small items.
The secondary efﬁ cacy parameters were (i) joint stiffness, 
evaluated on a similar scale, and (ii) an overall evaluation 
of discomfort from hand osteoarthritis after 3 months of 
treatment.
Taking an average of the 15 individual activities, the pain 
score showed a signiﬁ cant reduction in pain during treatment 
with rosehip powder (p<0.043) compared to placebo. A 
comparison of the placebo yielded a signiﬁ cant Mann-
Whitney p value of < 0.037. When evaluated on a yes/no 
basis, 88% reported pain reduction while on active treatment 
compared to 36% for the placebo group (p<0.009).
When the 15 individual activity items were examined one 
by one, the activity with the highest response, here deﬁ ned 
as the “high responder” was (xi) writing with a pen or pencil. 
A pre-treatment score of 5.00 ± 2.7 fell to 3.80 ± 2.6 after 
3 months of treatment with rosehip powder, a reduction of 
38%, compared to a non-signiﬁ cant drop from 5.00 ± 2.7 to 
4.8 ± 2.6 after 3 months of placebo treatment (p<0.008).
Further measures, such as stiffness and overall feeling 
of discomfort, declined signiﬁ cantly as a result of active 
treatment, as one would expect given the reduction in pain.
Data derived from several different studies indicates 
that rosehip powder is very well tolerated. Furthermore, 
the powder reduces pain and stiffness and improves ADL 
function in patients with osteoarthritis of various joints 
both in early and late stage osteoarthritis. The effect on 
pain seems to be of a sufﬁ cient magnitude to facilitate a 
reduction in the consumption of certain rescue medications 
normally used in osteoarthritis. The present data are also 
encouraging in light of the latest data on glucosamine5 and 
chondroitin sulfate,6 which as monotherapies seem less 
promising.
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Fig. 2. Flexion, external rotation and internal rotation of the hip 
as a percentage improvement in movement after 3 months active 
treatment patients and 3 months placebo treatment (* p<0.033). 
0
5
10
15
20
25
30
35
40
45
Flexion External Rotation Internal Rotation
Im
pr
ov
em
en
t %
Rosehip
Placebo
p < 0.033
ns
ns
Im
pr
o
v
em
en
t %
